A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

BACKGROUND: HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet, some HER2+ tumors do not benefit from anti-HER2 therapy. We hypothesize that HER2 amplification levels and PI3K pathway activation...

詳細記述

保存先:
書誌詳細
出版年:Ann Oncol
主要な著者: Veeraraghavan, J, Angelis, C De, Mao, R, Wang, T, Herrera, S, Pavlick, A C, Contreras, A, Nuciforo, P, Mayer, I A, Forero, A, Nanda, R, Goetz, M P, Chang, J C, Wolff, A C, Krop, I E, Fuqua, S A W, Prat, A, Hilsenbeck, S G, Weigelt, B, Reis-Filho, J S, Gutierrez, C, Osborne, C K, Rimawi, M F, Schiff, R
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2019
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594453/
https://ncbi.nlm.nih.gov/pubmed/30903140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdz076
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料